Fentanyl Overdose Crisis Causes, Risks, and Prevention

Posted on September 16, 2018

Introduction

Fentanyl is a potent synthetic opioid used medically for severe pain and anesthesia, but illicitly manufactured fentanyl has become a major driver of drug-overdose deaths in the United States. The public-health crisis is not caused primarily by properly prescribed pharmaceutical fentanyl. It is associated especially with illegally produced fentanyl and related substances entering heroin, counterfeit pills, cocaine, methamphetamine, and other drug supplies. Because fentanyl is highly potent and may be present without a user's knowledge, small errors in concentration can produce fatal respiratory depression. Effective prevention requires a combination of naloxone access, treatment for opioid use disorder, drug-checking and harm-reduction services, safer prescribing, public education, surveillance, and action against illegal supply (Centers for Disease Control and Prevention, 2025; National Institute on Drug Abuse, 2025).

What Fentanyl Is

Fentanyl is a synthetic opioid agonist that acts primarily at mu-opioid receptors. Pharmaceutical fentanyl is used in controlled medical settings because it can provide powerful analgesia and anesthesia. Its potency means dosing must be precise and patients may require close respiratory monitoring (National Institute on Drug Abuse, 2025).

Illicit fentanyl may be manufactured in clandestine laboratories and distributed as powder or pressed into counterfeit tablets designed to resemble legitimate prescription medicines. Users cannot determine fentanyl concentration through appearance, smell, or taste (Centers for Disease Control and Prevention, 2025).

Why Fentanyl Is So Dangerous

Opioids slow activity in brain pathways that regulate breathing. In overdose, breathing can become dangerously slow or stop completely. Fentanyl's potency and rapid action reduce the margin for error, particularly when people have low opioid tolerance or combine substances (National Institute on Drug Abuse, 2025).

The danger is increased by an unpredictable illegal supply. Two pills that look identical may contain

very different amounts of fentanyl. A person may believe they are taking oxycodone, alprazolam, or another drug while actually receiving fentanyl.

Counterfeit Pills

Counterfeit pills have become an important source of exposure because they can imitate prescription tablets in color, shape, and markings. They are not produced under regulated pharmaceutical quality controls (Centers for Disease Control and Prevention, 2025).

People should obtain prescription medicine only from licensed pharmacies based on legitimate prescriptions. Pills acquired through social media, friends, street markets, or unverified websites may contain unexpected substances.

Polysubstance Use

Fentanyl is increasingly detected with stimulants and other drugs. Some exposure is intentional, while some is not. Combining opioids with alcohol, benzodiazepines, or other central nervous system depressants can increase respiratory risk (National Institute on Drug Abuse, 2025).

Stimulants do not reliably “balance” opioids. A person can experience stimulant effects while respiratory depression continues. Overdose prevention should therefore address the entire drug supply rather than only people who identify themselves as opioid users.

Signs of Opioid Overdose

Possible signs include inability to wake, very slow or absent breathing, choking or gurgling sounds, limpness, pale or bluish skin, and pinpoint pupils. Not every sign is present in every case (Centers for Disease Control and Prevention, 2025).

Suspected overdose is a medical emergency. Emergency services should be contacted immediately, naloxone administered when available, and rescue breathing or cardiopulmonary resuscitation provided according to training and local guidance.

Naloxone

Naloxone is an opioid antagonist that can rapidly reverse opioid overdose by displacing opioids from receptors. It has no intoxicating effect and will not harm someone simply because the person’s unconsciousness was caused by a non-opioid condition (Centers for Disease Control and Prevention, 2025).

Because fentanyl can be potent and long acting relative to naloxone, more than one dose may sometimes be required. The person still needs emergency medical evaluation because overdose can recur after naloxone wears off.

Expanding Naloxone Access

Naloxone should be available to people who use opioids, their families, friends, community organizations, first responders, schools where appropriate, shelters, and other settings with overdose risk. Over-the-counter availability can reduce barriers.

Training should explain recognition, administration, rescue breathing, and emergency follow-up. Fear of stigma should not prevent people from carrying a medication capable of saving life.

Medication Treatment for Opioid Use Disorder

Opioid use disorder is a treatable medical condition. Medications such as buprenorphine and methadone reduce illicit opioid use and overdose mortality when appropriately provided. Extended-release naltrexone may be appropriate for selected patients after opioid abstinence (National Institute on Drug Abuse, 2025).

Treatment should not be framed as replacing one addiction with another. Medication stabilizes opioid receptors, reduces withdrawal and craving, and allows many patients to rebuild health and daily functioning.

Barriers to Treatment

Stigma, cost, transportation, limited treatment capacity, criminalization, housing instability, and fear of withdrawal can prevent people from receiving care. Requiring repeated failure or long waiting periods before medication increases risk.

Low-threshold treatment, same-day initiation, telehealth where appropriate, peer support, and integration with primary care can improve access.

Harm Reduction

Harm reduction accepts that some people will continue using drugs while still deserving protection from preventable death and disease. Services may include naloxone, sterile supplies, wound care, testing, treatment referral, and education (Centers for Disease Control and Prevention, 2025).

Harm reduction does not require approval of drug use. It recognizes that survival is necessary before

recovery or other change can occur.

Fentanyl Test Strips

Fentanyl test strips can detect the presence of fentanyl in many drug samples, helping users identify unexpected exposure. A negative result does not guarantee safety because sampling and test limitations remain.

Testing cannot measure an exact safe dose, and uneven distribution within a pill or powder can create dangerous “hot spots.” It should therefore be used as one layer of risk reduction rather than assurance.

Never Using Alone

Using drugs alone increases the likelihood that no one will be present to administer naloxone or call for help. Overdose-prevention programs encourage people to use with someone capable of responding or to use services that provide remote monitoring where available.

These recommendations reduce risk but cannot make an unpredictable illicit supply completely safe.

Tolerance

Opioid tolerance decreases after abstinence, incarceration, hospitalization, detoxification, or treatment interruption. Returning to a previously tolerated dose can then cause overdose (National Institute on Drug Abuse, 2025).

Discharge and release planning should therefore include naloxone, treatment linkage, and clear education about reduced tolerance.

Pain Treatment

Fentanyl has legitimate medical uses. Policies designed to reduce illegal fentanyl harms should not prevent appropriate pain or palliative care. Patients using prescribed opioids need individualized assessment, monitoring, and communication rather than abrupt abandonment.

Public discussion should distinguish pharmaceutical prescribing from illicit manufacturing so that patients are not stigmatized for receiving medically indicated treatment.

Prescription Opioid Stewardship

Clinicians should evaluate benefits and risks when prescribing opioids, use the lowest effective dose appropriate to the condition, review interactions, and reassess ongoing need. Non-opioid and nonpharmacologic treatments may be effective for many forms of pain.

Stewardship should not become rigid dose rules applied without context. Sudden discontinuation in a physically dependent patient can cause withdrawal and other harms.

Public Education

Education should explain that counterfeit pills may contain fentanyl, naloxone saves lives, and substance-use treatment is effective. Fear-based messages alone can increase stigma or cause audiences to dismiss information.

Messages are more useful when they provide concrete actions: obtain naloxone, avoid unverified pills, do not use alone, seek treatment, and call emergency services during suspected overdose (Centers for Disease Control and Prevention, 2025).

Young People

Adolescents may encounter counterfeit pills through social media or peers without identifying as regular drug users. Prevention should therefore include information about counterfeit medication rather than focusing only on heroin.

Schools and families should communicate in a way that allows young people to disclose use or exposure without assuming that punishment is the only response.

Stigma

Terms such as “addict” can reduce a complex health condition to an identity and discourage care. Person-first language such as “person with opioid use disorder” supports a medical and humane approach.

Stigma also affects families who may hide overdose or avoid obtaining naloxone. Public-health strategy should normalize evidence-based treatment and emergency response.

Surveillance

Timely overdose data help public-health agencies identify changes in substances, geography, and affected populations. Toxicology, emergency medical services, hospital records, and death certificates each provide different information (Centers for Disease Control and Prevention, 2025).

Data should guide local response rather than merely describe deaths after the fact. Rapid changes in the illegal drug supply require flexible systems.

Law Enforcement

Law enforcement has a role in targeting large-scale illegal manufacturing, trafficking, and fraudulent pill production. Enforcement alone cannot eliminate demand or treat opioid use disorder.

Public safety improves when criminal investigation is coordinated with health interventions and when people are not discouraged from calling for overdose help because they fear punishment.

Good Samaritan Policies

Many jurisdictions provide some legal protection to people who seek emergency assistance during an overdose. The details vary, so public information should explain local law accurately.

The policy purpose is to reduce hesitation during a time-sensitive medical emergency.

Community Response

Overdose prevention works best through cooperation among healthcare systems, treatment programs, harm-reduction organizations, families, public health, emergency services, schools, and community leaders.

Communities should examine who is dying and which barriers prevent care. A strategy effective in one city may need modification elsewhere.

Recovery

Recovery can include medication, counseling, peer support, housing, employment, family repair, and changes in social environment. There is no single pathway appropriate for every person.

Relapse should be treated as a signal to adjust treatment and safety planning rather than proof that

recovery is impossible.

Conclusion

The fentanyl overdose crisis is driven largely by an unpredictable illegal drug supply in which potent synthetic opioids appear in powders and counterfeit pills. Fentanyl can stop breathing rapidly, and people may be exposed without knowing it (Centers for Disease Control and Prevention, 2025; National Institute on Drug Abuse, 2025).

Preventing death requires practical tools: naloxone, medication treatment for opioid use disorder, harm reduction, safer prescribing, accurate education, rapid surveillance, and targeted action against illegal supply. The crisis cannot be solved through stigma or punishment alone. People must remain alive long enough to receive treatment, make choices, and recover.

References

Centers for Disease Control and Prevention. (2025). *Fentanyl facts and overdose prevention*.

National Institute on Drug Abuse. (2025). *Fentanyl DrugFacts*.